<DOC>
	<DOCNO>NCT00282048</DOCNO>
	<brief_summary>To determine activity response rate AG-013736 patient advance refractory renal cell cancer , ( patient also fail sorafenib-based therapy ) .</brief_summary>
	<brief_title>Study Of AG-013736 In Patients With Refractory Metastatic Renal Cell Cancer</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Renal Cell</mesh_term>
	<mesh_term>Kidney Neoplasms</mesh_term>
	<mesh_term>Axitinib</mesh_term>
	<criteria>RCC metastases nephrectomy failure prior sorafenibbased therapy least 1 target lesion irradiated adequate bone marrow , hepatic renal function , &gt; equal 18 year age . Gastrointestinal abnormality current use inability avoid chronic antacid therapy current use anticipate inability avoid potent CYP3A4 inhibitor CYP1A2 inducer active seizure disorder evidence brain metastasis .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>July 2012</verification_date>
</DOC>